Technologies for personalised cancer immunotherapies

Bookmark and Share
Published: 3 May 2016
Views: 2378
Prof James Heath - California Institute of Technology, Pasadena, USA

Prof James Heath speaks with ecancertv at AACR 2016 about neoantigens, a highly-personalised course of immunotherapy.

He explains the process of identifying and isolating mutant markers from a patients genome, to then process these novel targets as a T cell receptors.

He also discusses the current costs of therapy, considering the development of technology in recent years and looking forward to a future of faster, cheaper, patient-specific treatments.

For more on neo-antigens, you can view an interview with Dr Nicholas McGranahan about neoantigens in heterogenous tumours here.